Introduction of Long Acting Buprenorphine in France

Launched by UNIVERSITY OF BORDEAUX · Feb 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for people with opioid addiction using a long-acting version of buprenorphine, called Buvidal. Unlike traditional treatments that require daily doses, Buvidal can be given less frequently, which may help patients stick to their treatment plan and reduce the risk of misuse. The trial aims to gather more information about how effective this treatment is in real-life situations in France, focusing on how it affects patients' addiction severity, quality of life, and overall satisfaction with the treatment over a six-month period.

To participate in this study, individuals must be over 18 years old and have been prescribed Buvidal or plan to start treatment soon. They should also be able to understand and communicate in French. Participants will be asked to share their experiences and opinions about their treatment through surveys, helping researchers understand the benefits of Buvidal in managing opioid addiction. This study is important because it will help improve treatment options and support for those struggling with addiction.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • To have been prescribed LAB
• • To plan to initiate a LAB treatment in the following month
• • To be over 18 years of age
• • To accept to participate after an informed consent procedure
• Exclusion Criteria:
• • To be under guardianship, curatorship or safeguard of justice
• • To have a difficulty understand / reading the French language
• • To have any condition incompatible with study participation (e.g., not being able to communicate by phone)